Prolastin-C
Emphysema
Grifols Therapeutics LLCPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Emphysema cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Alpha-1-Proteinase Inhibitor CSL Behring | Phase 4 | BBB |
ce1226 CSL Behring | Phase 4 | BB |
.ALPHA.-1 PROTEASE INHIBITOR Sanofi | Phase 2 | B |
Kamada-Aat For Inhalation Kamada, Ltd. | Phase 2/3 | B |
Alvelestat Mereo BioPharma | Phase 2 | B |
View all 13 →
Same molecule, other indications
Prolastin-C is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →